Basic Dilantin Information

• INN (International Nonproprietary Name): Phenytoin
• Brand Names Available In United States: Dilantin, Phenytek
• ATC Code: N03AB02
• Forms & Dosages: Capsules (30 mg, 100 mg), Chewable Tablets (50 mg, 100 mg), Oral Suspension (125 mg/5 mL in 120 mL or 237 mL bottles), Extended Oral Capsules, Injectable Solution (50 mg/mL in 2 mL or 5 mL ampoules/vials)
• Manufacturers In United States: Pfizer, Mylan (Viatris), Sun Pharma, Teva, Sandoz, Accord Healthcare
• Registration Status In United States: FDA Approved For Seizure Control; Prescription Only
• OTC / Rx Classification: Prescription Only (Rx)

Key Findings From Recent Trials

Major 2022–2026 Studies

What did clinicians and emergency departments notice about phenytoin during 2022–2026?

There have been relatively few large randomized controlled trials of phenytoin in 2022–2026, with most high-quality evidence coming from comparative effectiveness analyses, emergency-room registries, and pharmacovigilance updates.

Registry data and observational cohorts continued to document the role of IV and IM phenytoin in acute seizure control and neurosurgery prophylaxis where fosphenytoin or levetiracetam are unavailable or cost-prohibitive.

Comparative analyses in those registries generally favored fosphenytoin for ease of IV administration, but kept phenytoin as an effective alternative when dosed and monitored correctly.

These findings align with long-standing clinical practice for tonic-clonic and complex partial seizures.

Main Outcomes

What were the typical clinical results reported?

Observational cohorts confirmed seizure suppression rates consistent with historical data when therapeutic plasma concentrations were maintained above the usual target range.

The target therapeutic band cited in surveillance reports is typically greater than 10 to 20 mcg/mL for total phenytoin concentration.

In acute settings, properly administered IV phenytoin produced seizure control comparable to prior standards when loading and maintenance doses accounted for patient weight and interactions.

Safety Observations

What safety signals were emphasized by postmarketing surveillance?

Recent safety surveillance reiterated known risks such as ataxia, nystagmus, gingival hyperplasia, hepatic enzyme elevations, and hematologic effects.

Reports emphasized phenytoin’s narrow therapeutic index and the frequent need for monitoring and dose adjustment in children, the elderly, and patients with hepatic impairment.

Registries continued to list severe skin reactions and blood dyscrasias as rare but important events to monitor.

Clinical Mechanism Of Action

Layman’s Explanation

How does phenytoin stop seizures in plain language?

Phenytoin reduces seizure activity by stabilizing electrical signaling in the brain, effectively slowing overactive nerve firing so seizures are less likely to spread.

That stabilizing effect is why clinicians prescribe Dilantin for generalized tonic-clonic and complex partial seizures.

Scientific Breakdown

What is the precise pharmacologic action behind that stabilization?

Phenytoin is a hydantoin derivative classified under ATC code N03AB02 that primarily blocks voltage-gated sodium channels in a use-dependent manner, reducing repetitive neuronal firing.

Use dependence means the drug preferentially affects neurons that are firing rapidly during a seizure.

Sodium Channel Kinetics

How does phenytoin alter sodium channel behavior?

Phenytoin preferentially binds the inactive state of voltage-gated sodium channels, which prolongs the refractory period of hyperactive neurons and reduces the ability of those neurons to fire repeatedly.

This binding explains why phenytoin is effective against sustained, rapid neuronal discharges seen in tonic-clonic seizures.

Pharmacokinetics & Protein Binding

What should prescribers and patients know about how the body handles phenytoin?

Phenytoin displays nonlinear or zero-order kinetics at higher doses, meaning small dose increases can disproportionately raise plasma concentrations.

High plasma protein binding is another hallmark, and low albumin states can increase free phenytoin levels even when total concentrations appear normal.

Because phenytoin is metabolized by the liver, hepatic impairment and drugs that change liver enzyme activity significantly affect clearance.

Therapeutic drug monitoring is standard, with typical targets for total phenytoin concentration cited as greater than 10 to 20 mcg/mL.

Scope Of Approved & Off-Label Use

United States Approvals

What are the FDA-approved uses of phenytoin?

In the United States, phenytoin (Dilantin) is FDA-approved for control of generalized tonic-clonic and complex partial seizures and for prevention and treatment of seizures during and after neurosurgery.

FDA-labeled formulations include capsules, chewable tablets, oral suspension, extended oral capsules, and an injectable solution at 50 mg/mL.

Common capsule strengths are 30 mg and 100 mg, and the oral suspension is typically 125 mg per 5 mL.

Notable Off-Label Trends

How do clinicians use phenytoin beyond labeled indications?

Off-label use includes emergency scenarios such as status epilepticus when fosphenytoin or levetiracetam are not accessible, and occasional lower-resource uses for neuropathic pain or arrhythmia management.

Many centers now favor alternatives like levetiracetam and valproate because those drugs have fewer interactions and more predictable kinetics, but phenytoin remains relevant where cost or supply is a limiting factor.

Dosage Strategy

General Dosing

How is phenytoin typically dosed for adults with epilepsy?

Typical adult oral regimens historically start at about 100 mg three times daily for tonic-clonic and partial seizures, with titration guided by blood levels and clinical response.

Because of nonlinear kinetics, small dose increases can cause large changes in plasma concentration, so clinicians use therapeutic drug monitoring to guide adjustments.

Condition-Specific Dosing

How do dosing approaches change in acute care or surgical prophylaxis?

For acute IV loading—such as for neurosurgery prophylaxis or status epilepticus—clinicians calculate weight-based loading doses, then follow with maintenance dosing tailored by levels and effect.

The injectable solution is supplied at 50 mg/mL in 2 mL or 5 mL ampoules, and institutional infusion protocols define safe loading and infusion rates.

Pediatric & Elderly Adjustments

What adjustments are needed for children and older adults?

Children often begin at approximately 5 mg/kg/day divided, with maintenance dosing in the range of 4 to 8 mg/kg/day as tolerated and guided by levels.

The elderly frequently require lower starting doses due to reduced clearance, and dose escalation should be conservative with close monitoring.

Patients with hepatic impairment need dose reduction and more frequent level checks because metabolism is impaired.

Safety Protocols

Contraindications

Who should not receive phenytoin?

Absolute contraindications include known hypersensitivity to phenytoin or other hydantoins and co-administration with delavirdine.

Severe hepatic impairment is a major caution, particularly for IV use, and product labeling highlights cardiovascular and neurologic monitoring when injecting.

Relative cautions include pregnancy because of teratogenic risk, renal or hepatic dysfunction, diabetes, porphyria, and certain cardiac conduction issues with IV administration.

Adverse Effects

What side effects are most common and which require urgent attention?

Common mild adverse effects include drowsiness, nausea, tremor, headache, dizziness, and gum overgrowth.

Moderate to severe adverse effects include nystagmus, ataxia, confusion, significant skin rashes including rare severe reactions, liver enzyme elevations, and blood dyscrasias.

Routine monitoring of complete blood counts, liver enzymes, and phenytoin plasma levels helps balance efficacy and toxicity.

Interaction Mapping

Food Interactions

What should patients do about meals and alcohol?

Take phenytoin consistently with regard to meals because changes in absorption or chronic alcohol use can alter plasma concentrations.

Formulation differences—such as between capsules, chewables, and suspension—can affect bioavailability, so patients should stick with the same formulation when possible.

Drug Combinations To Avoid

Which medications are most affected by phenytoin?

Phenytoin is a potent hepatic enzyme inducer and can reduce plasma levels and effects of many medications including oral contraceptives, warfarin, some statins, and certain antivirals.

Avoid coadministration with delavirdine per product labeling.

Drugs that inhibit CYP enzymes or displace protein binding can increase phenytoin levels and precipitate toxicity, so careful review and monitoring are required.

Enzyme Induction Specifics

How quickly do interactions manifest and what should prescribers expect?

Expect reduced efficacy of CYP-metabolized drugs over weeks as enzyme induction develops, meaning some interactions emerge gradually rather than immediately.

Conversely, CYP inhibitors can raise phenytoin concentrations rapidly, increasing the risk of adverse effects.

When starting or stopping interacting drugs, recheck phenytoin concentrations and adjust doses accordingly.

Patient Experience Analysis

Survey Data

What do patients say about living on phenytoin?

Patient surveys and clinic audits show satisfaction when seizures are controlled, but frequent complaints about side effects such as drowsiness, cognitive slowing, tremor, and gum hyperplasia persist.

Adherence challenges include the need for multiple daily doses for some formulations, regular blood-level monitoring, and noticeable adverse effects that affect quality of life.

Many patients report that reduced seizure frequency improves day-to-day functioning, even when they must tolerate some medication-related side effects.

Forum Trends

What practical issues do patients discuss online?

Online patient forums commonly raise concerns about gum care, switching formulations from capsules to suspension, confusion around monitoring levels, and pregnancy planning.

Comparisons between Dilantin and newer agents such as levetiracetam and lamotrigine show many patients preferring drugs with fewer interactions and less monitoring, although cost and access keep phenytoin relevant for some.

Distribution & Pricing Landscape

Market Overview

How is Dilantin supplied and who manufactures it?

Dilantin and generic phenytoin are distributed globally with major suppliers in the US and EU including Pfizer, Mylan (Viatris), Sun Pharma, Teva, Sandoz, and Accord Healthcare.

Commonly stocked formulations include 30 mg and 100 mg capsules, chewable tablets, 125 mg/5 mL oral suspension in 120 mL or 237 mL bottles, and 50 mg/mL injectable ampoules.

Pricing Dynamics

What affects cost and availability?

Generic competition usually lowers prices, but injectable stockouts or supply-chain constraints can cause regional price spikes for IV formulations.

Hospital formularies sometimes prefer fosphenytoin for IV dosing despite higher unit cost because of administration advantages, which also affects demand for phenytoin.

In our online pharmacy, dilantin is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table

What are common alternatives and how do they stack up in brief?

Levetiracetam offers easier dosing and fewer interactions and is often favored in acute and prophylactic settings.

Carbamazepine is effective for focal seizures but shares the enzyme-inducing profile of phenytoin.

Valproic acid is broad-spectrum but has important teratogenic risks and a different adverse effect profile.

Lamotrigine provides mood-stabilizing benefits and a better cognitive side-effect profile but requires slow titration.

Pros And Cons

Why choose phenytoin versus a newer agent?

Phenytoin advantages include well-established efficacy for tonic-clonic and partial seizures and availability in multiple formulations including injectable options.

Disadvantages include nonlinear kinetics, extensive drug interactions, monitoring burden, and cosmetic and systemic side effects such as gingival hyperplasia.

Choice of agent depends on seizure type, comorbidities, pregnancy considerations, and cost or access to alternatives.

Regulatory Status

Global Snapshots

How is phenytoin classified worldwide?

Phenytoin carries ATC code N03AB02 and is prescription-only in most countries, with brand names including Dilantin, Phenytek, and Epanutin among others.

Regulatory listings are similar across FDA, EMA, and national agencies, although exact product availability and local labeling may differ by country and over time.

Postmarketing Requirements

What safety monitoring do regulators emphasize?

Regulatory agencies stress pharmacovigilance for serious cutaneous reactions, hematologic events, hepatic injury, and teratogenicity.

Clinicians should consult national registries for current country-specific approvals and product formulations.

Consolidated FAQ

Quick Answers For Clinicians & Patients

What is Dilantin?

Dilantin is the brand name for phenytoin, an antiepileptic in the hydantoin class.

What forms are available?

Available forms include capsules (30 mg and 100 mg), chewable tablets (50 mg and 100 mg), oral suspension (125 mg/5 mL), extended-release capsules, and injectable solution at 50 mg/mL.

How is it monitored?

Monitoring includes therapeutic plasma levels, typically referenced as greater than 10 to 20 mcg/mL, liver enzymes, and complete blood counts.

Can pregnant patients use it?

Use only if necessary and after specialist counseling because of known fetal risks versus the need for seizure control.

What if a dose is missed?

Take as soon as remembered unless the next dose is near; do not double doses.

What are overdose signs?

Overdose symptoms may include ataxia, slurred speech, nystagmus, and in severe cases altered consciousness, and require immediate emergency care.

Visual Guide

Suggested Clinician Visuals

What clinician-facing visuals can reduce errors?

Create a one-page dosing and monitoring infographic with weight-based loading calculators, a therapeutic-level target band of greater than 10 to 20 mcg/mL, and a checklist for baseline labs including LFTs, CBC, and albumin.

Highlight injectable concentration at 50 mg/mL and common capsule strengths of 30 mg and 100 mg.

Patient-Facing Charts

What simple materials help patients adhere safely?

Provide a chart showing the formulation, dosing times, signs of toxicity to report, gum-care reminders, and contraception counseling for women of childbearing potential.

Dosing Flowchart Elements

Which steps belong on a dosing flowchart to prevent errors?

Include starting dose based on weight, baseline labs, loading and maintenance calculations, recheck of level at steady state, and slow titration reminders because of nonlinear kinetics.

Storage & Transport

Storage Guidance

How should pharmacies and patients store phenytoin?

Store at room temperature of 20 to 25°C or 68 to 77°F and protect from excessive moisture and light.

Keep oral suspensions, capsules, and chewables in intact packaging and out of reach of children.

Transport Considerations

What packaging steps reduce damage during shipping?

Injectable solutions in 2 mL or 5 mL ampoules require secure packaging to prevent breakage and contamination.

For international distribution cold chain is generally unnecessary, but avoid extreme heat and rotate stock to prevent expiry and verify authenticity.

Guidelines For Proper Use

Initiation & Follow-Up

How should therapy be started safely?

Begin with weight-appropriate dosing and baseline laboratory tests including liver enzymes, CBC, and albumin.

Use therapeutic drug monitoring to guide titration because of the nonlinear kinetics.

For IV use, follow institutional protocols for loading doses and infusion rates to minimize cardiovascular and neurologic complications.

Monitoring & Dose Adjustments

How often should levels and labs be checked?

Reassess plasma phenytoin concentrations after dose changes and at steady state, and adjust doses especially in elderly or hepatic impairment.

Watch for interacting medications that either induce clearance over weeks or inhibit clearance and raise toxicity risk rapidly.

Patient Counseling Points

What practical counseling reduces harm and improves adherence?

Emphasize consistent administration relative to meals and regular dental hygiene to mitigate gingival hyperplasia.

Instruct patients to report rashes or impaired coordination immediately and to seek specialist advice if pregnant or planning pregnancy.

Warn against abrupt discontinuation because that can provoke status epilepticus.

Delivery Across United States

Closing Notes For Clinicians

What practical checklist helps prescribers avoid common errors?

Confirm allergy and medication history, baseline LFTs, CBC, and albumin before initiating phenytoin therapy.

Calculate loading doses by weight for IV cases and use institutional infusion-rate limits to reduce cardiovascular risks.

Plan for therapeutic drug monitoring and anticipate interactions from enzyme induction when starting chronic therapy.

Use patient education tools such as the dosing flowchart and patient-facing adherence charts to support long-term safety.